Care for patients with dyslipidemia is rapidly changing. While statins are typically the first therapy to be prescribed for dyslipidemia, many patients are candidates for additional or alternative treatments that lower LDL-C and Lp(a) levels, as many patients are unable to tolerate high statin doses. In fact, up to two-thirds of patients are unable to reach their lipid goals with statin therapy alone. There are also emerging therapies in late-stage clinical trials which target new molecules or molecular pathways, or which provide more convenient routes of administration such as oral rather than injectable. New guidelines have been updated for the treatment of patients after an acute coronary syndrome by ACC/AHA/NAEMSP/SCAI, which recommend non-statin lipid-lowering therapy for high-risk patients if they are already on the maximal tolerated dose of statin therapy and their LDL-C levels remain ≥50 mg/dL for high-risk patients. Deciding which non-statin therapy to add to a patient’s background regimen depends on several factors, and not all clinicians may be aware of the most recent clinical trial data and current guidelines for the treatment of dyslipidemia.
In a previous program still available for credit here, Drs. Cannon, Bhatt, and O'Donoghue reviewed the landscape of non-statin drug treatments for hyperlipidemia, and in this program, they provide a timely and actionable update drawn from new lipid management data presented at the 2025 European Society of Cardiology (ESC) Congress in Madrid.
Cardiologists, lipidologists, and other healthcare providers who care for patients with dyslipidemia
Review updated pathophysiology of atherosclerosis, lipid science, current guidelines, and novel therapeutic targets to lower LDL-C and Lp(a) for patients with dyslipidemia
Analyze and contextualize newer clinical trial data for therapies to lower LDL-C levels as presented at ESC2025
Discuss how to utilize combinations of lipid-lowering therapies to improve long term outcomes for dyslipidemia patients with atherosclerosis
It is the policy of AcademicCME that all faculty, instructors, and planners disclose relevant financial relationships with ineligible companies. Planners have no relevant financial relationships with ineligible companies to disclose related to this activity. Faculty
have disclosed the following relevant financial relationships. All relevant financial relationships have been mitigated.
| Faculty | Relationship Identified With: |
| Christopher P. Cannon, MD (Course Chair) | Consultant/Advisor: Amgen Inc; Amryt Pharma; Ascendia Pharmaceutical Solutions; Biogen; Boehringer Ingelheim International GmbH; CHIESI Farmaceutici S.p.A.; CSL Behring; Genomadix; Janssen Pharmaceuticals, Inc; Lexicon Pharmaceuticals, Inc.; Lilly USA, LLC; Milestone Pharmaceuticals USA, Inc; Novartis AG; Pfizer Inc.; Rhoshan Pharmaceuticals, Inc.
Grant/Research Support: Amgen Inc; Areteia Therapeutics, Inc; Better Therapeutics Inc; Boehringer Ingelheim International GmbH; Bristol-Myers Squibb Company; Novo Nordisk A/S; ROMTherapy, Inc.; Veterans Administration |
| Deepak L. Bhatt, MD, MPH, MBA | Advisory Board: Angiowave; Antlia Bioscience; Bayer AG; Boehringer Ingelheim International GmbH; CellProthera; Cereno Scientific; E-Star Biotech; High Enroll; Janssen Pharmaceuticals, Inc, Level Ex; McKinsey; Medscape Cardiology; Merck & Co., Inc.; NirvaMed; Novo Nordisk A/S; Repair Biotechnologies; Stasys; Tourmaline Bio
Board of Directors: American Heart Association New York City; Angiowave (Stock Options); Bristol Myers Squibb (Stock); DRS.LINQ (Stock Options); High Enroll (Stock) Consultant: Alnylam; Altimmune; Broadview Ventures; Corcept Therapeutics; Corsera; GlaxoSmithKline; Hims; SERB; SFJ; Summa Therapeutics; Worldwide Clinical Trials Data Monitoring Committees: Acesion Pharma; Assistance Publique-Hôpitaux de Paris; Baim Institute for Clinical Research; Boston Scientific (Chair, PEITHO Trial), Cleveland Clinic; Contego Medical (Chair, PERFORMANCE 2); Duke Clinical Research Institute; Mayo Clinic; Mount Sinai School of Medicine (for the ABILITY-DM Trial, funded by Concept Medical; for ALLAY-HF, funded by Alleviant Medical); Novartis; Population Health Research Institute; Rutgers University (for the NIH-funded MINT Trial) Honoraria: American College of Cardiology (Senior Associate Editor, Clinical Trials and News, ACC.org; Chair, ACC Accreditation Oversight Committee); Arnold and Porter Law Firm (work related to Sanofi/Bristol-Myers Squibb clopidogrel litigation); Baim Institute for Clinical Research (AEGIS-II executive committee funded by CSL Behring); Belvoir Publications (Editor in Chief, Harvard Heart Letter); Canadian Medical and Surgical Knowledge Translation Research Group (clinical trial steering committees); CSL Behring (AHA lecture); Duke Clinical Research Institute; Engage Health Media; HMP Global (Editor in Chief, Journal of Invasive Cardiology); Medtelligence/ReachMD (CME steering committees); MJH Life Sciences; Oakstone CME (Course Director, Comprehensive Review of Interventional Cardiology); Philips (Becker's Webinar on AI); Population Health Research Institute; WebMD (CME steering committees); Wiley (steering committee) Other: Clinical Cardiology (Deputy Editor); Progress in Cardiovascular Diseases (Deputy Editor) Patent: Sotagliflozin (named on a patent for sotagliflozin assigned to Brigham and Women's Hospital who assigned to Lexicon; neither I nor Brigham and Women's Hospital receive any income from this patent) Research Funding: Abbott; Acesion Pharma; Afimmune; Alnylam; Amarin; Amgen; AstraZeneca; Atricure; Bayer AG; Boehringer Ingelheim International GmbH; Boston Scientific; CellProthera; Cereno Scientific; Chiesi; Cleerly; CSL Behring; Faraday Pharmaceuticals; Fractyl; Idorsia; Janssen Pharmaceuticals, Inc; Javelin; Lexicon; Lilly; Medtronic; Merck & Co., Inc.; MiRU; Moderna; Novartis AG; Novo Nordisk A/S; Pfizer; PhaseBio; Regeneron; Reid Hoffman Foundation; Roche; Sanofi; Stasys; 89Bio Royalties: Elsevier (Editor, Braunwald’s Heart Disease) Site Co-Investigator: Cleerly |
| Michelle L. O'Donoghue, MD, MPH | Consultant/Advisor: Amgen Inc; AstraZeneca; Janssen Pharmaceuticals, Inc; NewAmsterdam Pharma; Novartis AG; Novo Nordisk A/S; Verve Therapeutics, Inc.
Grant/Research Support: Amgen Inc; AstraZeneca; Marea Therapeutics, Inc.; Novartis AG |
Timothy Hayes, MD, PhD; Kim Cheramie, MSN, RN-BC; Chelsey Simonds; and Nicole McMenamin hereby state that they or their spouse/life partner do not have any relevant financial relationships to products or devices with any commercial interests related to the content of this activity of any amount during the past 12 months.
In support of improving patient care, AcademicCME is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
AcademicCME designates this enduring material for a maximum of 0.50 AMA PRA Category 1 CreditsTM.
Participants should claim only the credit commensurate with the extent of their participation in the activity.
This activity is supported by an educational grant from Merck & Co., Inc.
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. AcademicCME and Merck & Co., Inc. do not recommend the use of any agent outside of the labeled indications.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
In order to claim credit, participants must complete the following:
6. Learners should claim
For all CE inquiries or special needs, please contact admin@academiccme.com.
811 S. Orleans Ave. Tampa, Fl 33606
